Last reviewed · How we verify
Vi-CRM197 vaccine — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Vi-CRM197 vaccine (Vi-CRM197 vaccine) — Novartis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vi-CRM197 vaccine TARGET | Vi-CRM197 vaccine | Novartis | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vi-CRM197 vaccine CI watch — RSS
- Vi-CRM197 vaccine CI watch — Atom
- Vi-CRM197 vaccine CI watch — JSON
- Vi-CRM197 vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Vi-CRM197 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/vi-crm197-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab